Delving into the Latest Updates on Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Hemic and Lymphatic Diseases

Neoplasms

Synthetic peptide

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Synthetic peptide	1
Small molecule drug	1

Top 5 Target	Count

APB x LTA4H	1
GLP-1R(Glucagon-like peptide 1 receptor)	1

本研究考察健康受试者在空腹及餐后条件下，单次口服由浙江普洛康裕制药有限公司提供的丙戊酸钠缓释片（Ⅰ）【受试制剂，规格：0.5 g（以丙戊酸钠计）】或由赛诺菲（杭州）制药有限公司持证的丙戊酸钠缓释片（Ⅰ）【参比制剂，商品名：德巴金®，规格：0.5 g（以丙戊酸钠计）】的药动学特征，评价两制剂的生物等效性及安全性，为该受试制剂注册申请提供依据。

[Translation]

This study investigated the pharmacokinetic characteristics of sodium valproate sustained-release tablets (I) [test preparation, specification: 0.5 g (calculated as sodium valproate)] provided by Zhejiang Proconyu Pharmaceutical Co., Ltd. or sodium valproate sustained-release tablets (I) [reference preparation, trade name: Depakin®, specification: 0.5 g (calculated as sodium valproate)] certified by Sanofi (Hangzhou) Pharmaceutical Co., Ltd. in healthy subjects under fasting and postprandial conditions, evaluated the bioequivalence and safety of the two preparations, and provided a basis for the registration application of the test preparation.

Start Date04 Jun 2024

Sponsor / Collaborator

Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

CTR20241670 / CompletedNot Applicable

氟伐他汀钠缓释片在健康受试者中随机、开放、单剂量、两制剂、四周期、两序列完全重复交叉空腹和餐后状态下生物等效性试验

[Translation] A randomized, open-label, single-dose, two-formulation, four-period, two-sequence, fully repeated crossover bioequivalence study of fluvastatin sodium extended-release tablets in healthy subjects under fasting and fed conditions

本试验旨在研究单次空腹和餐后口服浙江普洛康裕制药有限公司生产的氟伐他汀钠缓释片（80mg）的药代动力学特征；以北京诺华制药有限公司生产的氟伐他汀钠缓释片（来适可®，80mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂在人体内的生物等效性。

[Translation]

This study aimed to study the pharmacokinetic characteristics of a single fasting and postprandial oral dose of fluvastatin sodium sustained-release tablets (80 mg) produced by Zhejiang Proconyu Pharmaceutical Co., Ltd.; using fluvastatin sodium sustained-release tablets (Lescol®, 80 mg) produced by Beijing Novatis Pharmaceuticals Co., Ltd. as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.

Start Date02 Jun 2024

Sponsor / Collaborator

Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

CTR20234297 / CompletedNot Applicable

磷酸奥司他韦干混悬剂在健康受试者中随机、开放、两制剂、单剂量、两周期、双交叉空腹和餐后状态下生物等效性试验

[Translation] A randomized, open-label, two-formulation, single-dose, two-period, double-crossover bioequivalence study of oseltamivir phosphate dry suspension in healthy subjects under fasting and fed conditions

主要研究目的：研究空腹和餐后状态下单次口服受试制剂磷酸奥司他韦干混悬剂（规格：0.36g，浙江普洛康裕制药有限公司生产，申请人浙江普洛康裕制药有限公司）与参比制剂磷酸奥司他韦干混悬剂（TAMIFLU®，规格：6mg/mL，Roche Registration GmbH持证，Roche Pharma AG生产）在健康成年受试者体内的药代动力学，评价空腹和餐后状态口服两种制剂的生物等效性。次要研究目的：评价健康受试者在空腹和餐后状态下，单次口服磷酸奥司他韦干混悬剂受试制剂和参比制剂后的安全性。

[Translation]

Main study objectives: To study the pharmacokinetics of the test preparation oseltamivir phosphate dry suspension (specification: 0.36g, produced by Zhejiang Proconyu Pharmaceutical Co., Ltd., applicant Zhejiang Proconyu Pharmaceutical Co., Ltd.) and the reference preparation oseltamivir phosphate dry suspension (TAMIFLU®, specification: 6mg/mL, certified by Roche Registration GmbH, produced by Roche Pharma AG) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary study objectives: To evaluate the safety of the test preparation and reference preparation of oseltamivir phosphate dry suspension in healthy subjects after a single oral administration in the fasting and fed state.

Start Date19 Jan 2024

Sponsor / Collaborator

Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

100 Clinical Results associated with Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

Login to view more data

2

Literatures (Medical) associated with Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

MoleculesQ3 · CHEMISTRY

Synthesis and Biological Evaluation of 1-(2-(6-Methoxynaphthalen-2-yl)-6-methylnicotinoyl)-4-Substituted Semicarbazides/Thiosemicarbazides as Anti-Tumor Nur77 Modulators

Q3 · CHEMISTRY

ArticleOA

Author: Zhang, Zhaolin ; He, Fengming ; Wu, Qi ; Zhao, Shengxian ; Huang, Jiangang ; Lin, Xianfu ; Hu, Hongyu ; Cao, Yin

Nur77 is an orphan nuclear receptor that participates in the occurrence and development of a variety of tumors. Many agonists of Nur77 have been reported to have significant anticancer effects. Our previous studies have found that the introduction of bicyclic aromatic rings, such as naphthalyl and quinoline groups, into the N′-methylene position of indoles’ Nur77 modulators can effectively improve the anti-tumor activity of the target compounds. Following our previous studies, a series of novel 1-(2-(6-methoxynaphthalen-2-yl)-6-methylnicotinoyl)-4-substituted semicarbazide/thiosemicarbazide derivatives 9a–9w were designed and synthesized in four steps from 6-methoxy-2-acetonaphthone and N-dimethylformamide dimethylacetal. All compounds were characterized by 1H-NMR, 13C-NMR and HRMS, and their anti-tumor activity on various cancer cell lines such as A549, HepG2, HGC-27, MCF-7 and HeLa are also evaluated. From the series of compounds, 9h exhibited the most potent anti-proliferative activity against several cancer cells. Colony formation and cell cycle experiments showed that compound 9h inhibited cell growth and arrested the cell cycle. Additionally, 9h leads to the cleavage of PARP. We initially explored the mechanism of 9h-induced apoptosis and found that compound 9h can upregulate Nur77 expression and triggered Nur77 nuclear export, indicating the occurrence of Nur77-mediated apoptosis. These results suggested that 9h may be a promising anti-tumor leading compound for the further research.

Zhongguo Yiyao Gongye Zazhi

Progress in study on derivatives of adamantane

Author: Chen, Xiao ; Ge, Xiaozhong ; Wang, Chengfa ; Ying, Huanghui ; Fu, Hongxing

A review.A review with 26 references on progress in study on derivatives of adamantane with subdivision headings: (1) antivirus effects; (2) for treatment of Parkinson's syndrome; (3) for treatment of chronic hepatitis C; (4) other usage and (5) the synthesis of derivatives of adamantane.

100 Deals associated with Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

Approved

Login to view more data